InnoSkel

InnoSkel is a pioneering platform biotechnology company developing treatments for rare skeletal diseases. InnoSkel is advancing a portfolio of therapies for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which is Spondyloepiphyseal Dysplasia Congenita (SEDc), the second leading cause of dwarfism worldwide. InnoSkel’s lead gene therapy asset for SEDc has demonstrated compelling efficacy in proof-of-concept studies. The company’s fundamental mission is to improve the lives of patients with skeletal dysplasia and address their unmet needs, ensuring their voices remain at the heart of everything we do.